I-Flow welcomes AcryMed as 2007 growth exceeds forecasts
This article was originally published in Clinica
Executive Summary
I-Flow, the Lake Forest, California-based manufacturer of pain management systems, said total sales for 2007 outpaced its expectations by increasing 24% to $116.5m. The company had previously forecast annual sales growth to be 20%. Sales of its regional anaesthesia products, which provide site-specific pain management, were also better than expected, growing 32% to $89.6m. In conjunction with its preliminary 2007 results, the firm announced the closing of its acquisition of AcryMed. I-Flow inked a $25m all-cash deal to buy the Beaverton, Oregon-based developer of silver-based infection control and wound healing technologies in December 2007 (see Clinica No 1287, p 12).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.